Journal Wrap | Early Tirofiban Improves Functional Outcomes Post Stroke; More
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.
OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions
Oral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the drug, according to new results from the phase 3 OASIS 4 trial, published in NEJM.
Sean Wharton, MD, et al., randomly assigned 307 patients (79% women; 92% White; mean age, 48 years) without diabetes and with overweight or obesity to oral semaglutide 25 mg (n=205) or placebo (n=102) once daily, plus lifestyle interventions. The trial included a 12-week dose escalation and a seven-week off-treatment follow-up, spanning 71 weeks with 64 weeks on therapy.
ATTAIN-1: Oral Orforglipron Significantly Reduces Weight, Cardiometabolic Risk
Orforglipron, a small-molecule, nonpeptide oral GLP-1 receptor agonist, at multiple doses produced significant weight loss and improved cardiometabolic risk factors compared with placebo, according to the phase 3 ATTAIN-1 trial, presented at the European Association for the Study of Diabetes General Assembly 2025 and simultaneously published n NEJM.
Sean Wharton, MD, et al., randomly assigned 3,127 patients (64% women; 57% White, 29% Asian; mean age, 45 years) with obesity and without diabetes in nine countries to orforglipron once daily at doses of 6 mg (n=723), 12 mg (n=725) or 36 mg (n=730) compared with placebo (n=949), in addition to healthy diet and physical activity.
ASSET-IT: Early Tirofiban Increases Functional Outcomes For Noncardioembolic Stroke
Early tirofiban significantly improved the likelihood of disability-free and functionally independent outcomes in patients with acute ischemic noncardioembolic stroke who receive thrombolysis within 4.5 hours after onset, according to results from the phase 3 ASSET-IT trial, published in NEJM.
Chunrong Tao, MD, PhD, et al., randomly assigned 832 patients (median age, 69 years; 36% women) from 38 centers in China to receive a 24-hour intravenous (IV) tirofiban infusion (n=414) or placebo (n=418) within 60 minutes following IV thrombolysis. Most patients (75%) received alteplase and 25% received tenecteplase. Treatment times were similar in both groups.
Clinical Topics: Cardiovascular Care Team, Dyslipidemia, Lipid Metabolism, Novel Agents
Keywords: Cardiology Magazine, ACC Publications, Glucagon-Like Peptide 1, Semaglutide, Weight Loss, Obesity, Urokinase-Type Plasminogen Activator, Tenecteplase, Intracranial Hemorrhages, Stroke
